Trifecta Capital Advisors’s Boston Scientific BSX Stock Holding History

Trifecta Capital Advisors’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13K	Sell	304 -48,012	-99%	-$2.61M	﹤0.01%	249
2026 Q1	$3.03M	Sell	48,316 -795	-2%	-$63.6K	0.47%	47
2025 Q4	$4.68M	Buy	49,111 +1,205	+3%	+$118K	0.69%	45
2025 Q3	$4.68M	Buy	47,906 +1,495	+3%	+$155K	0.71%	44
2025 Q2	$4.99M	Buy	46,411 +3,010	+7%	+$305K	0.83%	39
2025 Q1	$4.38M	Buy	43,401 +4,456	+11%	+$449K	0.92%	38
2024 Q4	$3.48M	Buy	38,945 +38,895	+77,790%	+$3.42M	0.69%	41
2024 Q3	$4.19K	Hold	50	–	–	﹤0.01%	244
2024 Q2	$3.85K	Hold	50	–	–	﹤0.01%	256
2024 Q1	$3.42K	Hold	50	–	–	﹤0.01%	255
2023 Q4	$2.89K	Hold	50	–	–	﹤0.01%	289
2023 Q3	$2.64K	Hold	50	–	–	﹤0.01%	278
2023 Q2	$2.71K	Hold	50	–	–	﹤0.01%	269
2023 Q1	$2.5K	Hold	50	–	–	﹤0.01%	283
2022 Q4	$2.31K	Buy	+50	New	+$2.17K	﹤0.01%	283

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Trifecta Capital Advisors's BSX Position: Q2 2026 in Review

Trifecta Capital Advisors reduced its Boston Scientific (BSX) stake by 99% in Q2 2026, selling an estimated $2.61M and leaving 304 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #249.

Trifecta Capital Advisors first reported a position in BSX in Q4 2022 and has held it in 15 quarters since. The position peaked at $4.99M in Q2 2025. 1,480 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Trifecta Capital Advisors held 304 shares of Boston Scientific worth $13K as of Q2 2026.
Trifecta Capital Advisors sold 48,012 Boston Scientific shares in Q2 2026, an estimated $2.61M.
Boston Scientific made up ﹤0.01% of Trifecta Capital Advisors's portfolio in Q2 2026, its #249 holding.
Trifecta Capital Advisors first reported a position in Boston Scientific in Q4 2022 and has held it in 15 quarters since.
Trifecta Capital Advisors's Boston Scientific position peaked at $4.99M in Q2 2025.
1,480 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Trifecta Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.